TRCT
BHVN icon

Tower Research Capital (TRC)’s Biohaven BHVN Stock Holding History

Tower Research Capital (TRC)’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Buy
13,280
+3,707
+39% +$40.6K ﹤0.01% 2090
2025
Q4 		$108K Buy
9,573
+3,001
+46% +$37.2K ﹤0.01% 1889
2025
Q3 		$98.6K Sell
6,572
-1,459
-18% -$21.2K ﹤0.01% 2004
2025
Q2 		$113K Buy
8,031
+5,341
+199% +$95.2K ﹤0.01% 2278
2025
Q1 		$64.7K Sell
2,690
-9,490
-78% -$335K ﹤0.01% 2039
2024
Q4 		$455K Buy
12,180
+11,781
+2,953% +$550K 0.01% 1135
2024
Q3 		$19.9K Sell
399
-15,180
-97% -$591K ﹤0.01% 3240
2024
Q2 		$541K Buy
15,579
+11,053
+244% +$437K 0.01% 1275
2024
Q1 		$248K Sell
4,526
-1,231
-21% -$61K 0.01% 1288
2023
Q4 		$246K Buy
5,757
+3,908
+211% +$122K ﹤0.01% 1928
2023
Q3 		$48.1K Sell
1,849
-4,828
-72% -$100K ﹤0.01% 2578
2023
Q2 		$160K Buy
6,677
+2,809
+73% +$48.4K 0.01% 1718
2023
Q1 		$53K Sell
3,868
-9,188
-70% -$146K ﹤0.01% 2432
2022
Q4 		$182K Buy
+13,056
New +$184K 0.01% 1364

Other funds holding BHVN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s BHVN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Biohaven (BHVN) stake by 39% in Q1 2026, buying an estimated $40.6K and bringing the position to 13,280 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #2090.

Tower Research Capital (TRC) first reported a position in BHVN in Q4 2022 and has held it in 14 quarters since. The position peaked at $541K in Q2 2024. 275 funds tracked by Wall St. Rank hold BHVN as of Q1 2026.

  • Tower Research Capital (TRC) held 13,280 shares of Biohaven worth $112K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,707 Biohaven shares in Q1 2026, an estimated $40.6K.
  • Biohaven made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2090 holding.
  • Tower Research Capital (TRC) first reported a position in Biohaven in Q4 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Biohaven position peaked at $541K in Q2 2024.
  • 275 funds tracked by Wall St. Rank held Biohaven as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.